Many patients find it more practical to continue at a lower maintenance dose rather than risk the full rebound cycle
In May 2023, Pfizer released the results of a Phase 2b clinical trial of the drug
Consideraciones importantes : Los medicamentos GLP-1 pueden causar efectos secundarios gastrointestinales como nuseas, vmitos, diarrea o estreimiento, especialmente al inicio del tratamiento
At Frisco Quick Care, we take the time to comprehensively evaluate your overall health, discuss potential benefits and risks, and create a personalized weight management plan tailored specifically to you
How safety data affects the approval timeline The dysesthesia signal will not necessarily prevent approval, but it will shape the labeling and potentially the approved dose range
Chemical & Handling Information Type: Synthetic multi-receptor peptide agonist Targets: GLP-1 receptor, GIP receptor, glucagon receptor (GCGR) Appearance: White to off-white lyophilized powder Specifications Peptide: Retatrutide Amount: 30 mg per vial Form: Lyophilized powder Purity: 99% (HPLC)
